Rheumatism is a chronic self-immunizing disease, and traditional drug treatments, such as anti-ruety drugs (DMARDs), are effective in controlling conditions in most patients, but some still respond poorly to traditional drugs. These patients need to be further assessed and integrated individualized treatment programmes developed.
When traditional drug treatment is less effective, the patient ‘ s condition should first be reassessed. Ensure that the diagnosis is accurate and excludes other diseases that may be similar to rheumatism, such as silver crumb arthritis, systemic red erythalamus, etc. Comprehensive examination of inflammatory indicators of patients, such as erythrocyte deposition rates (ESR), C Reactive Protein (CRP), type rheumatism factors (RF) and anti-accumuramate (CCP), with a detailed assessment of joint function and visual performance, and an understanding of the extent and progress of joint damage.
Biological agents are one of the important options for drug treatment. The cancer cause-alpha (TNF-alpha) inhibitor is a wider application of biological agents, such as Inassipe, Inflisi and Adam. They can specifically disrupt the biological activity of TNF-α, thereby reducing arthritis, pain and swelling and, to some extent, the progress of joint destruction. For patients with traditional DMARDs, the use of TNF-α inhibitors tends to significantly improve symptoms and signs. However, biological agents also have limitations that may increase the risk of infection, in particular tuberculosis, and therefore require rigorous pre-use screening, including for tuberculosis fungus, chest X-line examinations, etc., and close monitoring of infection signs in patients during use.
In addition to TNF-α inhibitors, there are other biological agents available. For example, white cell media – 6 (IL-6) receptor receptor beads are resistant to inflammation by inhibiting IL-6 signal access. The IL-6 receptor is likely to be more effective for patients who are ineffective or intolerant for TNF-α inhibitors. In addition, biological agents for B-cells, such as the one-on-one-on-the-Litutian resistance, can be used to reduce the generation of their own antibody by removing B-cells, and can be used for the treatment of incurable rheumatism.
Joint use is also one of the strategies for improving the efficacy of treatment. Based on the use of biological agents, traditional DMARDs, such as ammonium butterflies, can be combined. Studies have shown that the use of biological agents in combination with aminophosphate is more effective than the treatment of monopharmaceuticals, which can more effectively control the condition and reduce the risk of relapse. At the same time, other immunosuppressants such as fluoromette, nitrous sulfamide, etc. may be used jointly, depending on the patient ‘ s specific circumstances, but the adverse effects of the drug, in particular damage to the liver and kidney function and bone marrow inhibition, need to be closely monitored when using the combination.
In addition to drug treatment, non-pharmacological treatment is equally important. Rehabilitation treatment should be consistent, including physiotherapy and functional exercise. Physical therapy such as heat dressing, cold dressing, massage, acupuncture can alleviate joint pain and muscle stress and improve joint function. Functional exercise helps to increase muscle strength around joints, maintain joint activity and improve the patient ‘ s self-care capacity. For example, the movement of joint stretches, rotations and moderate aerobics, such as walking, swimming, etc.
Nutritional support cannot be ignored for such patients. It is recommended that patients follow the principle of anti-inflammatory diet and have ingestion of foods, such as fish oils, nuts, etc., rich in oxidizing substances, in order to reduce inflammation and increase the body ‘ s immunity.
In the case of patients with poor treatment of traditional drugs, a combination of re-evaluation of the condition, rational use of biological agents, joint use, non-pharmaceutical treatment and nutritional support is needed to develop individualized treatment programmes to better control the condition and improve the quality of life of patients. At the same time, the effects and adverse effects of treatment should be closely monitored and treatment strategies adjusted in a timely manner so that patients benefit from long-term disease management.
